Announcing Ablatotech's Leprovia clinical trials: an oral, natural GP-1 agonist-like weight loss drug. Learn how this breakthrough innovation aims to redefine weight management through cutting-edge research. Join Ablatotech's Liprovia Weight Loss Clinical Trial Are you ready to be part of a transformative step in healthcare innovation? Ablatotech, a leader in cutting-edge biotherapeutics, is conducting a clinical trial for Liprovia, a natural oral glucagon-like peptide-1 agonist-like (GLP-1 agonist-like) drug designed to redefine weight loss treatments. This breakthrough therapy aims to deliver a cost-effective, safer, and potentially more effective alternative to existing drugs on the market. By participating, you’ll play a vital role in helping us shape the future of medicine while accessing a scientifically advanced solution that empowers healthy and sustainable weight loss. Key Details: Seeking adults aged 18–65 with a BMI of 27 or higher. Participants will take the natural oral treatment daily over 12 weeks. Regular check-ins with expert healthcare providers to monitor progress. Why Join? Access to an innovative weight loss solution at no cost. Contribute to the development of a more affordable and effective weight loss option. Receive expert care and support throughout the study. How to Participate: Click here to learn more and enroll in the trial, or contact our clinical research team at info@ablatotech.com . Join us as we bring a groundbreaking, natural approach to weight management within reach for millions! Discover a Natural Solution for Weight Loss with Liprovia—Join Ablatotech’s Trial! Imagine a revolutionary weight loss solution that’s natural, safe, and effective—and now, imagine being part of the team that brings it to life. Ablatotech is inviting volunteers to join our clinical trial for an oral GP-1 agonist-like drug, a groundbreaking therapy designed to make weight loss affordable and accessible for everyone. ✨ Why You Should Join: Safer & Natural: Harness the power of nature for effective weight management. Groundbreaking Science: Help us pioneer a better, healthier alternative to current drugs. Completely Free: Join the trial and access this innovative solution at no cost. 📅 Enrollment is now open, but spaces are limited! Be a part of this healthcare revolution today. Use the form below to sign up now! Transform the future of weight loss—starting with yourself. Let’s Work Together Get in touch so we can start working together. First Name Last Name Email Location Phone Year of Birth Your height (inches) Your weight (lbs) Race Select race Ethnicity Select Ethnicity Gender Select a gender Condition Choose an option I accept terms & conditions View terms of enrollment Sign Up Submitted. Thanks for your interest in Liprovia clinical trials

Get in touch with Ablatotech. Reach out to us for inquiries about our groundbreaking innovations, clinical trials, or collaborations. We're here to help and answer your questions. What's on your mind? Get in touch with Ablatotech. Reach out to us for inquiries about our groundbreaking innovations, clinical trials, or collaborations. We're here to help and answer your questions. Please reach out by using this form or email us - info@ablatotech.com info@ablatotech.com First Name Last Name Email Message Send Thanks for submitting!

Terms of Use for Participation in Tarysol Clinical Trials at Ablatotech Effective Date: 02/12/2025 Last Updated: 3/14/2025 1. Acceptance of Terms By applying to participate in the Tarysol clinical trials conducted by Ablatotech, you acknowledge that you have read, understood, and agreed to abide by these Terms of Use. Your application does not guarantee inclusion in the study; final selection is determined after a detailed screening process. 2. Purpose of Clinical Trial The Tarysol Clinical Trials aim to evaluate the safety, efficacy, and potential applications of Tarysol, a natural compound designed to rapidly solubilize blood clots in veins. By participating, you contribute to medical research aimed at improving healthcare solutions. 3. Voluntary Participation Participation in this trial is entirely voluntary. You may choose to withdraw your application or discontinue your participation in the trial at any time without consequence. 4. Eligibility Requirements You must meet the eligibility criteria established for the trial, including but not limited to: Age, gender, and health requirements specific to the trial. Absence of certain pre-existing medical conditions as determined by our screening questionnaire or health assessments. 5. Screening and Selection Applicants will undergo a thorough screening process that includes: Completion of detailed questionnaires. Submission of medical records and other requested documentation. Possible physical and diagnostic evaluations. Disclosure of all medications or treatments being used. Ablatotech reserves the right to decline any applicant who does not meet the trial’s criteria or poses a health risk. 6. Privacy and Data Protection Your personal and medical information will be treated as confidential and stored securely. Ablatotech complies with applicable data protection laws such as HIPAA (Health Insurance Portability and Accountability Act) and GDPR (General Data Protection Regulation). Data collected during the trial may be used for research purposes in a de-identified manner. 7. Risks and Benefits Participants must understand the following: Risks: Use of Tarysol may involve side effects, allergic reactions, or unforeseen adverse events. These will be communicated during the informed consent process. Benefits: While personal benefits cannot be guaranteed, participation may contribute to advancements in the treatment of skin disorders. 8. Informed Consent You must sign an Informed Consent Form before participating in the trial. This document provides detailed information about the study, its purpose, procedures, potential risks, and benefits. 9. Participant Responsibilities By participating in the Tarysol clinical trials, you agree to: Follow all instructions provided by the research team. Report any side effects, adverse events, or concerns promptly. Attend all scheduled visits and comply with study protocols. Failure to meet these responsibilities may result in removal from the trial. 10. Compensation Ablatotech may offer compensation for participation, including reimbursement for travel and related expenses. The details of compensation will be outlined before enrollment. 11. Medical Care and Support In the event of injury or adverse effects related to participation in the trial, appropriate medical care will be provided by Ablatotech or its affiliated partners. Details regarding the extent of medical care will be specified in the Informed Consent Form. 12. Termination of Participation Ablatotech reserves the right to terminate your participation in the trial if: You no longer meet the eligibility requirements. You fail to comply with study protocols. Continuation in the trial is deemed unsafe or inappropriate. 13. Intellectual Property Any discoveries, data, or intellectual property resulting from the clinical trial shall remain the sole property of Ablatotech. Participants have no claim to ownership or compensation beyond what is outlined in this document. 14. Limitation of Liability Ablatotech is not liable for any damages beyond those specified in the informed consent, except as required by law. 15. Amendments to Terms Ablatotech reserves the right to modify these Terms of Use at any time. Participants will be notified of any significant changes, and continued participation constitutes acceptance of the revised terms. 16. International Participation Clinical trials for Tarysol are currently open only to individuals residing outside of the United States. Applicants from international locations will be evaluated under the same rigorous standards as domestic participants. 17. Pre-screening medical questionaire Providing answers to the pre-screening medical questionaire is voluntary. If providing that information, you could remain anonymous by not providing your last name. 18. Contact Information For questions, concerns, or further information, please contact us at: Email: info@ablatotech.com Acknowledgment and Agreement: By submitting an application for the Tarysol clinical trials, you affirm that you have read and understood these Terms of Use and agree to abide by them.

Be a Pioneer in Transforming Global Healthcare with Ablatotech At Ablatotech, we believe in a future where healing isn’t a privilege but a right accessible to all. With your help, we can make that vision a reality. By signing up for our future clinical trials, you will play a vital role in advancing life-changing medical breakthroughs that have the power to redefine global healthcare. Why Join Our Mission? Empower Innovation: Your participation drives research that unlocks the body’s natural potential to heal itself, paving the way for safer, more effective treatments. Make a Difference: Be part of solutions that bring cutting-edge healthcare to underserved populations worldwide. Shape the Future: Together, we can pioneer technologies that revolutionize medicine and transform lives on a global scale. At Ablatotech, every clinical trial is a step toward groundbreaking progress. Your willingness to be involved could lead to treatments that touch countless lives. Sign Up Today Join our growing community of visionaries. By registering for future clinical trials, you’ll be the first to know about exciting opportunities to participate in research that truly matters. Help us shape a healthier tomorrow. Together, we can revolutionize medicine—one trial at a time. Please signup below, today. Your contribution today will help change lives tomorrow. First Name Last Name Email Location Phone Year of Birth Race Select a Race Ethnicity Enter your ethnicity Gender Select a gender Condition Choose an option I agree to the terms & conditions View terms of use Sign Up Submitted! Thanks for your interest in Ablatotech clinical trials.

Terms of Use for Participation in Nygela Clinical Trials at Ablatotech Effective Date: 02/12/2025 Last Updated: 3/14/2025 1. Acceptance of Terms By applying to participate in the Nygela clinical trials conducted by Ablatotech, you acknowledge that you have read, understood, and agreed to abide by these Terms of Use. Your application does not guarantee inclusion in the study; final selection is determined after a detailed screening process. 2. Purpose of Clinical Trial The Nygela clinical trial aims to evaluate the safety, effectiveness, and tolerability of Nygela, a topical, natural, steroid-free cream designed to treat skin disorders such as psoriasis, acne, and eczema. By participating, you contribute to medical research aimed at improving healthcare solutions. 3. Voluntary Participation Participation in this trial is entirely voluntary. You may choose to withdraw your application or discontinue your participation in the trial at any time without consequence. 4. Eligibility Requirements You must meet the eligibility criteria established for the trial, including but not limited to: Age, gender, and health requirements specific to the trial. Absence of certain pre-existing medical conditions as determined by our screening questionnaire or health assessments. 5. Screening and Selection Applicants will undergo a thorough screening process that includes: Completion of detailed questionnaires. Submission of medical records and other requested documentation. Possible physical and diagnostic evaluations. Disclosure of all medications or treatments being used. Ablatotech reserves the right to decline any applicant who does not meet the trial’s criteria or poses a health risk. 6. Privacy and Data Protection Your personal and medical information will be treated as confidential and stored securely. Ablatotech complies with applicable data protection laws such as HIPAA (Health Insurance Portability and Accountability Act) and GDPR (General Data Protection Regulation). Data collected during the trial may be used for research purposes in a de-identified manner. 7. Risks and Benefits Participants must understand the following: Risks: Use of Nygela may involve side effects, allergic reactions, or unforeseen adverse events. These will be communicated during the informed consent process. Benefits: While personal benefits cannot be guaranteed, participation may contribute to advancements in the treatment of skin disorders. 8. Informed Consent You must sign an Informed Consent Form before participating in the trial. This document provides detailed information about the study, its purpose, procedures, potential risks, and benefits. 9. Participant Responsibilities By participating in the Nygela clinical trials, you agree to: Follow all instructions provided by the research team. Report any side effects, adverse events, or concerns promptly. Attend all scheduled visits and comply with study protocols. Failure to meet these responsibilities may result in removal from the trial. 10. Compensation Ablatotech may offer compensation for participation, including reimbursement for travel and related expenses. The details of compensation will be outlined before enrollment. 11. Medical Care and Support In the event of injury or adverse effects related to participation in the trial, appropriate medical care will be provided by Ablatotech or its affiliated partners. Details regarding the extent of medical care will be specified in the Informed Consent Form. 12. Termination of Participation Ablatotech reserves the right to terminate your participation in the trial if: You no longer meet the eligibility requirements. You fail to comply with study protocols. Continuation in the trial is deemed unsafe or inappropriate. 13. Intellectual Property Any discoveries, data, or intellectual property resulting from the clinical trial shall remain the sole property of Ablatotech. Participants have no claim to ownership or compensation beyond what is outlined in this document. 14. Limitation of Liability Ablatotech is not liable for any damages beyond those specified in the informed consent, except as required by law. 15. Amendments to Terms Ablatotech reserves the right to modify these Terms of Use at any time. Participants will be notified of any significant changes, and continued participation constitutes acceptance of the revised terms. 16. International Participation Clinical trials for Nygela are currently open only to individuals residing outside of the United States. Applicants from international locations will be evaluated under the same rigorous standards as domestic participants. 17. Pre-screening medical questionaire Providing answers to the pre-screening medical questionaire is voluntary. If providing that information, you could remain anonymous by not providing your last name. 18. Contact Information For questions, concerns, or further information, please contact us at: Email: info@ablatotech.com Acknowledgment and Agreement: By submitting an application for the Nygela clinical trials, you affirm that you have read and understood these Terms of Use and agree to abide by them.